In the following video, health care editor/analyst David Williamson discusses the recent analyst upgrade that sent shares of Keryx Pharmaceuticals soaring 30% over the last couple of trading sessions. After handing back perifosine to its partner Aeterna Zentaris, Keryx is regaining momentum after a successful phase 3 trial of its other drug candidate, Zerenex. To find out whether this newfound bullish sentiment is deserved, watch the video and Fool On.
David Williamson owns shares of Pfizer, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. Motley Fool newsletter services have recommended buying shares of Pfizer. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.